Targeting IL-6 in cholangiocarcinoma therapy.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 17897336.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this issue of the Journal, Cheon and coworkers have examined the utility of serum IL-6 values as a biomarker for cholangiocarcinoma (CCA). Serum IL-6 values were increased in patients with CCA as compared to controls or patients with hepatocellular carcinoma. IL-6 levels also correlated with tumor thickness (a surrogate for tumor burden) as examined by intraductal ultrasonography, a novel approach for assessing CCA tumor burden. Following photodynamic therapy, serum IL-6 values decreased. This study suggests IL-6 may be a biomarker for CCA, confirms the efficacy of photodynamic therapy (PDT) as an antineoplastic therapy, and implies that targeted IL-6 therapy may be beneficial in CCA.
Medical subject headings
- Bile Duct Neoplasms
- Bile Ducts, Intrahepatic
- Cholangiocarcinoma
- Interleukin-6